3. Member



Introducing our founders and scientific & technical adviser


Founder, Representative Director Takao Hamakubo, Ph.D., MD

iTAP technical guidance, antibody medicine and immunology guidance

Ph.D. at Kyoto University School of Medicine. Professor Emeritus, The University of Tokyo.

Formerly a professor at the Research Center for Advanced Science and Technology, University of Tokyo, and a professor at the Institute for Advanced Medical sciences, Nippon Medical School before assuming his current position.

Fields of biochemical research, developing methods for analyzing membrane protein expression and antibody production. A leading expert in the development of antibody drugs.

Founder, Director Yasuhiko Bando

Company management, business development, novel target discovery (proteogenomics)

MSA at St. Michael’s College (US).

He has established several biotechnology-related companies since 1987 and has been challenging new models of drug discovery based on these analytical technologies, which are attracting worldwide attention.

He has collaborated with many overseas companies, including Lund University (Sweden), and has a laboratory at the Research Center for Advanced Science and Technology, University of Tokyo, where he is bringing new results in drug screening technology and clinical proteogenomics.

Founder, Director Nobuyuki Tanaka

Company management, business development

Nobuyuki Tanaka holds a master’s degree from the Graduate School of Arts and Sciences (Science Fundamentals) at the University of Tokyo, and became a director of software developer Dream Technologies in 2002, where he achived M&As and corporate restructuring, and experienced business responsibilities in multiple industries.

After working in new business development and consulting, he has been the representative of Early Reflection, Inc. since 2014. Incubation of scientific and technological seeds.

Director Makoto Yamada

He worked for a domestic pharmaceutical company as a pharmaceutical information officer, marketing, and business development department. He then joined DEFTA Partners, where he was responsible for investment and management support in the biotechnology, drug discovery, medical device, digital health, and health tech fields.

He has been a director (outside) of PhotoQ3, Inc. since June 2022.

Technical Advisor

Harubumi Kato, Ph.D., MD, Science and Technology Advisor

PDT technical support, clinical trial guidance

Director, Japan Lung Cancer Research Center Director Emeritus, Niiza Shiki Central General Hospital Professor of Respiratory Surgery, Tokyo Medical University before assuming his current position.

He is a world authority on lung cancer treatment.

Inventor and leader of photodynamic therapy (PDT), a laser therapy for early-stage lung cancer, and recipient of the Gold Medal Award at the 17th International Photodynamic Society.